Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Hereditary angioedema (HAE) is a rare, autosomal dominant disorder characterized by recurrent attacks of subcutaneous or sub-mucosal oedema. Laryngeal attacks are potentially life threatening, the patients are at risk of suffocation during the attack.
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Hereditary angioedema (HAE) caused by C1 inhibitor deficiency (C1-INH-HAE) is characterized by recurrent episodes of disabling swelling. Recombinant human C1 inhibitor (rhC1-INH) is approved for treatment of HAE attacks. A treatment registry was established in Europe to review the safety and efficacy of rhC1-INH.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
